Enwei Pharmaceutical Co

Enwei Pharmaceutical Co FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Enwei Pharmaceutical Co (301331.SZ) as of Oct 21, 2026 is 102.44 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 76.50 % — a change of 33.90% (higher).

FCF Conversion

102.44 %

YoY

33.90%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Enwei Pharmaceutical Co is 2025 102.44 % . FCF Conversion Rate (FCF/EBITDA) of Enwei Pharmaceutical Co was 2024 76.50 % . It decreases by 33.90% higher compared to the previous year.

The Enwei Pharmaceutical Co FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2019
119.22 CNY
Jan 1, 2020
47.96 CNY
Jan 1, 2021
48.52 CNY
Jan 1, 2022
57.22 CNY
Jan 1, 2023
-57.97 CNY
Jan 1, 2024
76.50 CNY
Jan 1, 2025
102.44 CNY
The Enwei Pharmaceutical Co FCF Conversion history
YEARFCF ConversionYoY
102.44 %+33.90%
76.50 %-231.96%
-57.97 %-201.32%
57.22 %+17.93%
48.52 %+1.17%
47.96 %-59.77%
119.22 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Enwei Pharmaceutical Co Stock analysis

What does Enwei Pharmaceutical Co do? Enwei Pharmaceutical Co., Ltd. generates revenue through the research, development, production, and sales of proprietary Chinese and chemical medicines. The company's main products include Jieeryin lotion, Jieeryin ointment, Jieeryin effervescent tablets, Shanmai Jianpi oral liquid, Qingjing capsules, and Danxiong Tongmai granules, which are primarily sold via direct sales and e-commerce channels. Its focus on gynecological products, pediatric medicines, and respiratory medicines targets domestic consumers seeking specialized healthcare solutions. The firm's domestic market strategy emphasizes direct customer engagement and online sales to reach its target segments. The company's product portfolio is tailored to specific health needs, with Jieeryin products addressing gynecological concerns, Shanmai Jianpi oral liquid supporting digestive health, Qingjing capsules for gynecological treatments, and Danxiong Tongmai granules targeting cardiovascular health. These offerings are distributed through direct sales teams and e-commerce platforms, aligning with the domestic market's preference for accessible healthcare products. Enwei's domestic focus ensures that its products meet local regulatory standards and consumer demands. Enwei Pharmaceutical's revenue streams are driven by the consistent demand for its specialized medicine categories, particularly in gynecology, pediatrics, and respiratory care. The firm's domestic market presence allows it to build strong relationships with healthcare providers and end-users, facilitating repeat purchases and brand loyalty. By concentrating on these key therapeutic areas, Enwei effectively serves its core customer segments without expanding into international markets. Enwei Pharmaceutical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Enwei Pharmaceutical Co stock

FCF Conversion Rate (FCF/EBITDA) of Enwei Pharmaceutical Co is 102.44 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Enwei Pharmaceutical Co changed from 76.50 % to 102.44 %, representing a 33.90% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Enwei Pharmaceutical Co since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Enwei Pharmaceutical Co with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Enwei Pharmaceutical Co

All Key Metrics — Enwei Pharmaceutical Co